SCHEMBL2910978

SCHEMBL2910978

CCOC(=O)c1cccc(N(Cc2ccncc2)c2ccc(F)c(OC)c2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.45
BRAF P15056 1/20 0.40
HSD17B2 P37059 1/20 0.40
TSHR P16473 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPK1 P28482 2/20 0.39
NPC1 O15118 2/20 0.39
MEP1B Q16820 1/20 0.39
LTC4S Q16873 1/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
POLB P06746 1/20 0.38
CDC25B P30305 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
SREBF1 P36956 1/20 0.38
LMNA P02545 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2909628 0.90 GRM2 (0.43) NAMPTBRAFALDH1A1MAPTKDM4E
SCHEMBL2905225 0.88 TAS2R14 (0.45) MAPK1MEP1BLTC4SPOLBKDM4C
SCHEMBL2906999 0.87 MEP1B (0.43) HSD17B2TSHRHSD17B10MAPK1NPC1
SCHEMBL2909130 0.82 KMT2A (0.46) NAMPTTSHRHSD17B10MAPK1NPC1
SCHEMBL2910411 0.77 GRM2 (0.46) NAMPTMEP1BALDH1A1KDM4C
SCHEMBL1157752 0.77 GRM2 (0.44) BRAFHSD17B2ALDH1A1MAPTKDM4E
SCHEMBL3129767 0.77 PDE4B (0.46)
SCHEMBL1157339 0.75 MAPT (0.42) NPC1ALDH1A1MAPTKDM4EHPGD
SCHEMBL1157641 0.75 PDE4A (0.53) MAPT
SCHEMBL1157628 0.75 GRM2 (0.41) ALDH1A1MAPTKDM4EPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B NAMPT 953/4885BRAF 3417/4885HSD17B2 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.